• 1
    Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007; 72; 725.
  • 2
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235; 177182.
  • 3
    Bartlett JMS. Biological predictors of tumour response: natural selection or intelligent design? Advances Breast Cancer 2005; 2; 1115.
  • 4
    Miller WR, Bartlett JMS, Canney P, Verrill M. Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Res. Treat. 2007; 103; 149160.
  • 5
    Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366; 20872106.
  • 6
    Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747752.
  • 7
    Bartlett JMS. Translational research and the development of novel biomarkers in breast cancer. Advan Breast Cancer 2006; 3; 7685.
  • 8
    Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007; 72; 725.
  • 9
    Tovey SM, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JMS. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin. Cancer Res. 2005; 11; 48354842.
  • 10
    Johnston SRD, Head J, Pancholi S et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin. Cancer Res. 2003; 9; 524S532S.
  • 11
    Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JMS. Expression of the HERI-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 2003; 200; 290297.
  • 12
    Kirkegaard T, McGlynn LM, Campbell FM et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin. Cancer Res. 2007; 13; 14051411.
  • 13
    Kirkegaard T, Witton CJ, McGlynn LM et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol. 2005; 207; 139146.
  • 14
    Cannings E, Kirkegaard T, Tovey SM, Dunne B, Cooke TG, Bartlett JMS. Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res. Treat. 2007; 102; 173179.
  • 15
    Bergqvist J, Elmberger G, Ohd J et al. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur. J. Cancer 2006; 42; 11041112.
  • 16
    Gutierrez MC, Detre S, Johnston S et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 2005; 23; 24692476.
  • 17
    Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226; 466468.
  • 18
    Di Leo A, Chan S, Paesmans M et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res. Treat. 2004; 86; 197206.
  • 19
    Di Leo A, Gancberg D, Larsimont D et al. HER-2 Amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 2002; 8; 11071116.
  • 20
    Di Leo A, Larsimont D, Gancberg D et al. HER-2 and topo-isomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann. Oncol. 2001; 12; 10811089.
  • 21
    Jarvinen TAH, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 2000; 156; 839847.
  • 22
    Jarvinen TAH, Kononen J, Peltohuikko M, Isola J. Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am. J. Pathol. 1996; 148; 20732082.
  • 23
    Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin and fluorouracil: Danish breast cancer cooperative group. J. Clin. Oncol. 2005; 23; 74837490.
  • 24
    Pritchard KI, Shepherd LE, O’Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 2006; 354; 21032111.
  • 25
    Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res. 2001; 61; 53455348.
  • 26
    Paik S, Bryant J, Tan-Chiu E et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J. Natl Cancer Inst. 2000; 92; 19911998.
  • 27
    Moliterni A, Menard S, Valagussa P et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J. Clin. Oncol. 2003; 21; 458462.
  • 28
    Poole CJ, Earl HM, Hiller L et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N. Engl. J. Med. 2006; 355; 18511862.
  • 29
    Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003; 21; 22372246.
  • 30
    Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290; 21492158.
  • 31
    Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350; 21292139.
  • 32
    Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. U. S. A. 2004; 101; 1330613311.
  • 33
    Cappuzzo F, Gregorc V, Rossi E et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J. Clin. Oncol. 2003; 21; 26582663.
  • 34
    Parra HS, Cavina R, Latteri F et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer. Br. J. Cancer 2004; 91; 208212.
  • 35
    Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J. Pathol. 2003; 199; 411417.
  • 36
    Hirsch FR, Varella-Garcia M, McCoy J et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 2005; 23; 68386845.
  • 37
    Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO. Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv. Anat. Pathol. 2005; 12; 271273.
  • 38
    Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 1992; 13; 317.
  • 39
    Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat. 1994; 29; 4149.
  • 40
    Tovey SM, Witton CJ, Bartlett JMS, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 2004; 6; R246R251.
  • 41
    Rampaul RS, Pinder SE, Wencyk PM et al. Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value? Clin. Cancer Res. 2004; 10; 2578.
  • 42
    Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 53675374.
  • 43
    Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006; 25; 58465853.
  • 44
    Reis-Filho JS, Pinheiro C, Lambros MB et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J. Pathol. 2006; 209; 445453.
  • 45
    Kersting C, Kuijper A, Schmidt H et al. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab. Invest. 2006; 86; 5461.
  • 46
    Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum. Pathol. 2007; 38; 11051122.
  • 47
    Chan SK, Hill ME, Gullick WJ. The role of the epidermal growth factor receptor in breast cancer. J. Mammary Gland Biol. Neoplasia. 2006; 11; 311.
  • 48
    Smith IE, Walsh G, Skene A et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol. 2007; 25; 38163822.
  • 49
    Witton CJ, Reeves JR, Going JG, Cooke TG, Bartlett JMS. Coexpression of EGFr, HER2, HER3 and HER4 in primary human breast carcinoma. Breast Cancer Res. Treat. 2001; 69; 32.
  • 50
    Burris HA III, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 2005; 23; 53055313.
  • 51
    Carter TA, Wodicka LM, Shah NP et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. U. S. A. 2005; 102; 1101111016.
  • 52
    Fujita T, Doihara H, Kawasaki K et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br. J. Cancer 2006; 94; 247252.
  • 53
    Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6; 117127.
  • 54
    Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275; 19431947.
  • 55
    Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002; 62; 41324141.
  • 56
    Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol. Cancer Res. 2007; 5; 195201.
  • 57
    Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer 2003; 4; 126137.
  • 58
    Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005; 16; 525537.
  • 59
    Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124; 471484.
  • 60
    Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307; 10981101.
  • 61
    Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8; 179183.
  • 62
    Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer 2004; 91; 14201424.
  • 63
    Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 2001; 19; 38083816.
  • 64
    Mauriac L, Keshaviah A, Debled M et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann. Oncol. 2007; 18; 859867.
  • 65
    Hammond MEH, Taube SE. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin. Oncol. 2002; 29; 213221.
  • 66
    McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 2006; 100; 229235.